You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

NORETHINDRONE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for norethindrone and what is the scope of freedom to operate?

Norethindrone is the generic ingredient in thirteen branded drugs marketed by Parke Davis, Dr Reddys Labs Sa, Aurobindo Pharma, Glenmark Pharms Ltd, Lupin Ltd, Janssen Pharms, Teva Branded Pharm, Amneal Pharms, Naari Pte Ltd, Novast Labs, Xiromed, Duramed Res, Aurobindo Pharma Ltd, and Barr, and is included in twenty-five NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-six drug master file entries for norethindrone. Sixteen suppliers are listed for this compound. There are two tentative approvals for this compound.

Drug Prices for NORETHINDRONE

See drug prices for NORETHINDRONE

Drug Sales Revenue Trends for NORETHINDRONE

See drug sales revenues for NORETHINDRONE

Recent Clinical Trials for NORETHINDRONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bio Genuine (Shanghai) Biotech Co., Ltd.Phase 3
Myovant Sciences GmbHPhase 4
University of ChicagoPhase 4

See all NORETHINDRONE clinical trials

Generic filers with tentative approvals for NORETHINDRONE
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up1MG;0.01MG;75MGTABLET;ORAL
⤷  Sign Up⤷  Sign Up75MGTABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for NORETHINDRONE
Drug ClassProgestin
Medical Subject Heading (MeSH) Categories for NORETHINDRONE

US Patents and Regulatory Information for NORETHINDRONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glenmark Pharms Ltd NORETHINDRONE norethindrone TABLET;ORAL-28 091209-001 Jul 22, 2010 AB2 RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Xiromed NORETHINDRONE norethindrone TABLET;ORAL-28 201483-001 Jun 24, 2013 AB1 RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Duramed Res AYGESTIN norethindrone acetate TABLET;ORAL 018405-001 Apr 21, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dr Reddys Labs Sa ERRIN norethindrone TABLET;ORAL-28 076225-001 Oct 21, 2002 AB2 RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Xiromed NORETHINDRONE norethindrone TABLET;ORAL-28 200980-001 Jun 12, 2013 AB2 RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Naari Pte Ltd NORETHINDRONE norethindrone TABLET;ORAL-28 206807-001 Dec 13, 2016 AB1 RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Branded Pharm NOR-QD norethindrone TABLET;ORAL-28 017060-001 Approved Prior to Jan 1, 1982 AB1 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.